While prior clinical trials of inhaled IFN-β in unselected asthma populations and initiated after symptom onset showed limited efficacy (40), our data argue for a prophylactic strategy targeted toward individuals with documented low IFN tone, administered early in the course of infection or during high-risk seasons. The gene discussed is IFNB1; the disease is asthma.